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Reteplase (rPA) is a thrombolytic agent used for the treatment of acute myocardial infarction. We studied the expression of rPA
and its selected asparagine mutants after integration into the Pichia genome. Though methanol induction of the native and
the rPA mutants showed similar expression levels (∼200–250mg/L), the mutants displayed signiﬁcant loss of protease activity.
Strikingly, the clot lysis activities of these mutants were considerably diﬀerent. While mutation of Asn
12 (N12P) of the Kringle 2
domain showed delayed clot lysis activity (t1/2 = 38min) compared to the native rPA (t1/2 = 33min), a faster rate of clot lysis
(t1/2 = 27min) was observed when the Asn
278 (N278S) of the serine protease domain was mutated. Interestingly, the slowest clot
lysis activity (t1/2 = 49min) demonstrated by the double mutant (N12P, N278S) suggests the dominant role of Asn
12 in regulating
the ﬁbrinolytic activity of rPA. The results presented in this paper indicate that the ﬁbrinolytic and the proteolytic activities of rPA
are independent of each other.
1.Introduction
Thrombolysis is the ﬁrst choice of therapy for acute myocar-
dial infarction (AMI). The most common thrombolytic
agents (TAs) include streptokinase (ﬁrst generation TA) and
alteplase (second generation TA, tissue plasminogen activa-
tor,tPA).ThethirdgenerationTAs’likerPA,tenecteplaseand
lanoteplase, are some of the derivatives of alteplase. Human
tPAisa70kDaserineproteasewithtwoformsTypeItPAand
TypeIItPAwithmajordiﬀerencesintheircoreglycosylation.
There are four potential N-linked glycosylation sites for tPA
at positions Asp-117, -184, -218, and -448.
The tPA molecule contains ﬁve discrete structural
domains. In the presence of plasmin, single-chain tPA, or
zymogen enzyme can be cleaved into an activated two-
chain form. The heavy chain contains four of these domains:
a “ﬁnger” domain which is homologous to a portion of
ﬁbronectin; a “growth factor” domain which is homologous
to epidermal growth factor; two nonequivalent “Kringle”
domains. The light chain contains the serine protease
domain, which is homologous to trypsin and chymotrypsin.
It is reported that plasmin cleavage occurs C-terminal to
Kringle 2 (at Arg278) to form two-chain tPA [1].
Reteplase (recombinant plasminogen activator, rPA) is
a thrombolytic agent approved by the Food and Drug
Administration (http://en.wikipedia.org/wiki/Food and Dr-
ug Administration) in 1996 for the management of acute
myocardial infarction (AMI) in adults, in the reduction of
the incidence of congestive heart failure, and for reduction
of mortality associated with AMI. It is a single-chain
deletion mutant of tPA containing C-terminal kringle 2
and serine protease domains of tPA which includes, 3552 Advances in Hematology
amino acids with a total molecular weight of 39kDa. The
protease domain is responsible for converting plasminogen
to plasmin, which in turn degrades the ﬁbrin matrix of
thrombuswhilethekringle2domainbindsspeciﬁcallytothe
ﬁbrin clot. Because of the deletion of the ﬁbronectin ﬁnger
region, the binding of rPA to ﬁbrin is signiﬁcantly reduced in
comparison with that of alteplase. In clinical trials, rPA has
demonstrated more rapid and complete coronary patency
compared with alteplase, without signiﬁcant increase in the
clinical adverse events [2, 3].
The rPA molecule is a nonglycosylated protein form of
human tPA eﬃciently produced in E. coli containing 1–3
and 176–527 amino acids of tPA. Such an engineered rPA
molecule carries three potential N-glycosylation sites at Asn-
184, -218 and -448 with a consensus sequence Asn-Xaa-
Ser/Thr from human tPA. The asparagine positions in the
rPA are Asn-12, -48, and -278, respectively.
rPA has been expressed in various expression hosts like
Bacillus subtilis [4], seaweed of Laminaria japonica [5],
mammalian system [6–8], yeast like Pichia methanolica [9],
Pichia pastoris [10, 11], fungal systems [12], and insect cells
[13], and so forth. The expression levels of rPA between all
these systems vary considerably with problems of protein
instability.WhilealotofliteratureexistsonexpressionofrPA
in bacterial system like E. coli [14–16], the method involves
long and ineﬃcient renaturation procedures [17]w i t hp o o r
recovery during downstream operations [18].
Pichia pastoris is a well-known yeast used by researchers
worldwideforexpression ofproteinsin solubleform[19–22]
due to its advantages like robustness, growth in chemically
deﬁned media, shorter fermentation times as compared to
mammalian system, eﬀective glycosylation, absence of endo-
toxins, achieving high-cell density, and so forth. Although
reports on expression of rPA in methylotrophic yeast Pichia
pastoris are available, the yield is merely 100mg/L by
conducting fermentation studies at the usual temperature
of 30
◦C[ 11]. A further lower temperature of 20
◦C during
fermentation was found to enhance the expression levels to
200mg/L [11]. Addition of glycerol to the cultures has been
reported to enhance the levels of rPA expression to nearly
200mg/L when the fermentation is carried out at 30
◦C[ 23].
Zou and Chu [24] have studied the host’s enzyme activity
during rPA production phase by recombinant Pichia pastoris
with not much stress on expression levels.
In the present paper, we report the successful gener-
ation of Pichia recombinants carrying multiple copies of
rPA gene integrated into Pichia genome by homologous
recombination. Such high-geneticin-resistant Pichia pastoris
recombinants expressed rPA to reasonably appreciable level
of 250mg/L as judged by ELISA in shake ﬂask studies.
Moreover, one could observe stable expression of rPA during
the entire induction period of 72 h. Considering the signiﬁ-
cance of asparagine residues of N-linked glycosylation sites
in maintaining structural integrity and catalytic function
of proteases [25, 26], we attempted to investigate the role
of asparagines involved in the N-linked glysosylation sites
present in activity regulating domains of rPA. When the
native rPA gene was subjected to site directed mutagenesis
(SDM) to modify the potential asparagine linked glycosy-
lation sites, we found dramatic reduction in the protease
activity of all the mutants with insigniﬁcant changes in their
expression levels. Interestingly, the rate of clot lysis was
enhanced by 20% when the mutation was in the protease
domain while it reduced by 20% when the asparagine
mutation was in the kringle 2 domain of rPA.
2.MaterialsandMethods
2.1. Yeast Strains, Plasmids, Enzymes and Reagents.
Escherichia coli DH5α, PCR reagents, restriction and
ligation enzymes, SDS-PAGE reagents were procured from
Bangalore Genei, Bangalore (India). Oligos, gel puriﬁcation
kit and PCR puriﬁcation kits were obtained from Sigma
(USA). Plasmid pPIC9K, Pichia pastoris strain GS115, Pichia
expression kit (Spheroplast module) and geneticin were
purchased from Invitrogen (Carlsbad, CA USA). Luria
Bertani broth (LB), LB agar, yeast extract, bacto peptone,
yeast nitrogen base (YNB) without amino acids were from
BD (USA). Dextrose, sorbitol, amino acids and D-biotin for
selection of Pichia transformants were procured from Sigma
(USA). Site directed mutagenesis kit (Quick Change II ) was
obtained from Stratagene, USA. Chromozym t-PA substrate
(N-Methylsulfonyl-D-Phe-Gly-Pro-Arg-4nitroanilideaceta-
te) was procured from Roche, Germany while human
plasminogen, human ﬁbrinogen and human thrombin were
from Sigma, USA. The chromogenic substrate D-Val-Leu-
Lys 4-nitroanilide dihydrochloride used for plasminogen
activation assay was purchased from Sigma, USA. The
polyclonal rabbit anti-rPA IgG and goat antirabbit IgG-HRP
antibodieswerepurchasedfromAbexomeBiosciences,India.
2.2. PCR Ampliﬁcation and Cloning of rPA Gene. rPA gene
was custom synthesized at GenArt (Germany) and used as a
template for PCR ampliﬁcation. The PCR was carried out in
50μL volume with forward primer 5  GGG GTA TCT CTC
GAG AAA AGA TCT TAC CAA GGC AAC AGC GAT 3 
and reverse primer 5  CCG CCG GAA TTC TAC GTA TTA
GGC TCG CAT GTT GTC ACG AAT 3  using two step PCR
programme: initial denaturation at 94
◦Cf o r4m i nf o l l o w e d
by 5 cycles of 94
◦C for 30sec, 50
◦Cf o r3 0s e c ,a n d7 2
◦Cf o r
90sec; and 25 cycles of 94
◦C for 30sec, 60
◦Cf o r3 0s e ca n d
72
◦C for 1min with ﬁnal extension 7min at 72
◦C. The1.1kb
PCRproductwasdigestedwithXhoIandSnaBIenzymesand
clonedintopPIC9KcutwithXhoI/SnaBIenzymes.Theclone
development was carried out in DH5α cells. The clones were
conﬁrmed by restriction analysis and DNA sequencing.
2.3. SDM of rPA Gene at Asparagine Residues. The oligos
designed for the mutation of asparagine residues are shown
in Table 1. Brieﬂy, the pPIC9K-rPA DNA was subjected to
site directed mutagenesis using Stratagene’s Quick Change
kit. The PCR was carried out in 50μL volume and the
PCR conditions were according to manufacturer’s protocol.
After the PCR, the mix was treated with DpnIf o r1 ha t
37
◦C and used to transform the DH5α cells. The mutant
clones were selected by restriction analysis. Asn12 and Asn278Advances in Hematology 3
Table 1: Oligos used for carrying out SDM of wild type (native)
rPA gene.
Asn
12
FP: 5  GGC AAC AGC GAT TGC TAT TTT GGC
CCC GGG AGC GCG TAT CGC GGC ACC 3 
RP: 5  GGT GCC GCG ATA CGC GCT CCC GGG
GCC AAA ATA GCA ATC GCT GTT GCC 3 
Asn
278
FP: 5  GC ACA TCA CAA CAT TTA CTT TCT AGA
ACA GTC ACC GAC AAC 3 
RP: 5  GTT GTC GGT GAC TGT TCT AGA AAG
TAA ATG TTG TGA TGT GC 3 
residues which are potential sites of N-linked glycosylation
were selected for SDM.
2.4. SDM Conﬁrmation by Restriction Analysis. The clone
carrying mutation at Asn12 of the rPA gene created Sma1 site
(N12P), the Asn278 mutation created a XbaI site (N278S).
The clone carrying double mutation at Asn12 and Asn278
contained both XbaIa n dSmaI site (N12P, N278S). The
clones carrying mutations of rPA gene were subjected to
PCR separately using AOX primers as described above and
the puriﬁed PCR products were subjected to restriction
digestion using appropriate restriction endonucleases for
easy identiﬁcation of successful SDM.
2.5. Transformation of P. pastoris Strain GS115 with Lin-
earized DNA of pPIC9K-rPA and Its Mutants and Selection
of Geneticin Resistant Clones. Spheroplasting of P. pastoris
strain GS115 was carried out using Pichia expression kit by
following manufacturer’s protocol (Invitrogen, CA, USA).
Spheroplasted GS115 cells were transformed with 10μgo f
the SalI linearized pPIC9K-rPA plasmid and the transfor-
mants were plated on histidine deﬁcient RDB (containing
1.34% (w/v) yeast nitrogen base, 2% (w/v) dextrose, 1M
Sorbitol, 0.005% (w/v) amino acids, 4 × 10
−5% (w/v)
biotin and 2% (w/v) agar) medium for the selection for
His+ phenotypes. All His+ transformants were picked up
and grown in YPD broth for 48hrs at 30
◦Ca n dw e r e
then spotted on YPD agar plates with geneticin at three
diﬀerent concentrations, namely, 0.5mg/mL, 1mg/mL, and
2mg/mL. There are extensive reports of hyper expression
of foreign proteins from higher geneticin resistant Pichia
transformants, since such transformants carry high copy
numbers of the integrated genes [7, 8]. Transformants with
highest geneticin resistance, which carry multiple copies of
the integrated rPA gene, were further conﬁrmed for rPA gene
insertion by colony PCR using AOX1 sequencing primers
(Invitrogen,CA,USA).AtypicalPCRreactionwassetupina
25μL reaction volume that consisted of initial denaturation
at 95
◦C for 5min followed by 30 cycles of 95
◦Cf o r3 0s e c ,
55
◦C for 30sec, and 72
◦C for 1min with a ﬁnal extension
at 72
◦C for 7min. Clones showing right size PCR product
and highest geneticin resistance were chosen for expression
studies.
2.6. Expression of Native rPA and Its Mutants in Shake Flask.
Single colony from each of the transformants was inoculated
into 50mL BMGY (buﬀered complex glycerol medium)
separatelyandgrownat30
◦Cfor48h.Thecultur eswer ecen-
trifugedat4000rpmfor10minandpelletswereresuspended
in10mLBMMY(buﬀeredcomplexmethanolmedium).The
methanol was added at 1% ﬁnal concentration daily for
three days. The expression of rPA was checked by running
supernatant fraction on 12% SDS-PAGE and visualized by
silver staining.
2.7.QuantitationofrPAinPichiaSupernatantby ELISA. The
supernatant from the induced Pichia culture was dialyzed
against 10mM Tris pH 7.6 and used for the quantitation of
rPA by direct ELISA. The primary and secondary antibodies
were rabbit anti-rPA IgG and goat antirabbit IgG-HRP,
respectively, and the substrate was TMB. The yield of the rPA
was calculated using retavase as standard and expressed as
mg/L.
2.8. Biological Activity of the rPA
2.8.1. Protease Assay. Enzymatic activity of rPA was mon-
itored by direct cleavage of the chromogenic substrate
Chromozym t-PA (N-Methylsulfonyl-D-Phe-Gly-Pro-Arg-4
nitroanilide acetate) as per manufacturer’s protocol with
some modiﬁcations as described below. Brieﬂy, 6.25μLo f
samples were incubated with 62.5μL of 9-fold diluted chro-
mozym t-PA solution (4mM) in 96-well plate and incubated
for 30minutes at room temperature in dark. 100mM Tris,
pH 8.5 served as reagent blank. The substrate was cleaved
by rPA resulting in the formation of yellow colored 4-
nitraniline (pNA) which was measured at 405nm after
stopping the reaction using 31.25μL citric acid (10%, w/v).
Blank subtracted absorbance was represented as relative
activity of the samples [27]. Bacterial derived rPA (retavase)
was used as a positive control and for comparison studies.
2.8.2. Clot Lysis Assay. Fibrin gel (100μL/reaction) was
prepared in a 96-well ﬂat bottom plate by incubating a
mixture of human ﬁbrinogen (250μg), human plasminogen
(1μM), and human thrombin (1U) per reaction at 37
◦Cf o r
30min.Thedissolutionoftheclotswasmonitoredat340nm
by a plate reader (Multiskan Spectrum, Thermo) at diﬀerent
time points (0, 15, 30, 45, 60min) after addition of 100μLo f
Pichia culture supernatants on the surface of the clot. The
plate was incubated at 37
◦C for the speciﬁed time period
and continuously shaken at 400rpm. The % ﬁbrin gel lysis
was calculated by extrapolating the readings of the respective
wells at O.D. 340nm considering the reading of the well
containingmediumonlyandwithoutthrombinas100%clot
lysis. The ﬁbrinolytic activity of the samples was quantitated
by the lysis time (t1/2) which is the time needed to reduce the
turbidity of the clot to the half-maximal value [28].
2.8.3. Plasminogen Activation Assay. Plasminogen activation
by rPA was determined by a chromogenic assay as previously
described [19]. Brieﬂy, 25mU of human plasminogen,
chromogenic substrate D-Val-Leu-Lys 4-nitroanilide dihy-
drochloride and samples containing rPA were incubated in4 Advances in Hematology
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Figure 1: Plasmid map of pPIC9K-rPA.
96-well ﬂat-bottom plates (Nunc) at 25
◦C for 30min. rPA
activatesplasminogentoformplasmin,whichinturncleaves
the chromogenic substrate to release yellow coloured pNA
which was measured at 405nm by a plate reader.
3. Results
3.1. Construction of pPIC9K-rPA Clone. The rPA gene
sequence includes 1–3 amino acids of the ﬁnger domain and
176–527 amino acids of K2S domains of the tPA molecule.
The clone was conﬁrmed by restriction analysis and DNA
sequencing. The plasmid map constructed is shown in
Figure 1.
3.2. Conﬁrmation of SDM for rPA Mutants. The PCR prod-
uct of reteplase gene isolated from pPIC9K-rPA construct
and its SDM mutants were examined for the digestion
with the respective restriction endonucleases. The results
(Figure 2(a))indicatethatSmaIdigestionofN12PgaveDNA
fragments of expected sizes, namely, 750bp, 400bp, 386bp,
and 260bp while N278S clone yielded two fragments of
1184bp and 440bp upon XbaI digestion.
3.3. Transformation of GS115 Cells and Expression of Native
rPA Molecule. Pichia pastoris host GS115 cells were trans-
formed with linearized pPIC9K-rPA DNA by spheroplasting
method. The Pichia recombinant which showed resistance
to 2mg/mL geneticin was selected for rPA expression in
shake ﬂasks. Initial expression of rPA in the BMMY medium
with 1% methanol was very less (data not shown). However,
this expression was improved to higher yield by addition of
Tween-80 to a ﬁnal concentration of 0.1%. The molecular
weight of recombinant native rPA (WT) was ∼55kDa. This
was further conﬁrmed by Western blot studies (data not
shown).
3.4. Generation of Pichia Recombinants Carrying Asaparagine
Substitutions and Analysis. Asn12 and Asn278 residues which
are the two potential sites of N-linked glycosylation were
selected for SDM. These asparagine residues were changed
to proline and serine, respectively, just to enable creation
of a restriction site for further conﬁrming the mutation
reaction.TheHis+ geneticinresistantcoloniesweresubjected
to integration PCR using AOXI speciﬁc primers as per the
protocoldescribedbyApte-Deshpnadeetal.[19].Theresults
in Figure 2(b) show successful integration of rPA gene into
Pichia genome as evident by the right size PCR product.
3.5. Amino Acid Sequence Comparisons between WT rPA and
Its Mutants. The amino acid sequence comparisons between
native and asparagine rPA mutants is depicted in Figure 3.
The data shows the modiﬁed asparagine residues in the
mutants studied.
3.6. Expression of Recombinant rPA from P. pastoris in Shake
Flasks. The predicted molecular weight of the native rPA
is 39kDa while on SDS-PAGE it showed a diﬀused band
with a molecular weight of ∼55kDa (Figure 4). This is
expected since glycosylated proteins are known to exhibit
higher molecular weight on SDS-PAGE. The SDS-PAGE for
supernatants from all the SDM mutants also showed similar
expression levels. The Asp-48 was not chosen for modiﬁ-
cation for this study since the consensus sequence of the
tripeptide acceptor sequeon is Asn-Pro-Thr, where proline
is known to prevent the N-linked glycosylation [1]. The
other mutations did show reduced N-linked glycosylation
since the proteins showed a clear band (Figure 4)o fe x p e c t e d
sizes, 43kDa for N12P and N278S and 39kDa for the double
mutant (N12P, N278S).
3.7. Quantitation of rPA by ELISA. The expression levels
of the rPA from the native as well as the SDM mutants
were estimated by ELISA using anti-rPA polyclonal antibody.
The amount of rPA expressed correlated well with the
observations of SDS-PAGE and the yields of the native and
its mutants showed expression levels in the range of 210–
250mg/L (Figure 5).
3.8. Biological Activity of rPA and Its Mutants
3.8.1. Protease Activity by Chromozym t-PA Assay. The native
r P Ac l o n e( W T )s h o w e dp r o t e a s ea c t i v i t ya sc o m m e r c i a l l y
available rPA preparation (retavase), the clones carrying
asparagine mutations (N12P, N278S and N12P, N278S) lost
their protease activity signiﬁcantly (P<. 0001). Notably, the
activity was signiﬁcantly decreased (P<. 001) in the double-
mutated rPA molecule (N12P, N278S) compared to that of
single mutated clones like N12P or N278S (Figure 6(a)).
3.8.2. Clot Lysis Activity Assay by Turbidimetric Fibrinolytic
Assay. Activity of rPA was represented as the rate of clot lysis
by turbidimetric ﬁbrinolytic assay. Similar to Chromozym t-
PA assay, double mutated rPA clone (N12P, N278S) resulted
in most delayed activity (t1/2 = 49mins) as compared to
the WT rPA of (t1/2 = 33min). Very interestingly, single
mutation of the Asn12 (N12P) of the Kringle 2 domain,Advances in Hematology 5
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Figure 2: (a) Restriction analysis of the PCR product of pPIC9K-rPA mutated constructs. M: lambda EcoR1/HindIII digest, lane 1: PCR
productfromN12Pclone+Sma1;lane2:N278Sclone+XbaI;lane3:N12P,N278S+Xba1/Sma1.(b)IntegrationPCRofPichiarecombinants
carrying native rPA gene. M: lambda EcoR1/HindIII digest; lanes 1–4 geneticin resistant clones of Pichia carrying ppIC9K-reteplase gene and
its mutants integrated into its genome. Lane 1: N12P clone; lane 2: N278S; lane 3; N12P, N278S; lane 4: WT reteplase.
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Figure 3: Amino acid sequence comparisons between native and rPA SDM mutants. Bold line indicates kringle 2 domain while dotted
line indicates the serine protease domain. The asaparagine substitutions have been boxed. Reteplase refers to WT rPA gene while modiﬁed
reteplase refers to mutated rPA gene.
known for its ﬁbrin selectivity, also showed delayed activity
(t1/2 = 38min), presumably indicating the loss of ﬁbrin-
binding. However, the ﬁbrinolytic activity of N278S (t1/2 =
27min) remain unaﬀected indicating the noncritical nature
ofthisasparagineforclotlysis.ItisclearfromtheFigure 6(b)
that Pichia-derived crude rPA variant (N278S) is better than
retavase as far as clot lysis activity is concerned supporting
our earlier observations of chromozym protease assay. This
data clearly indicate that ﬁbrinolytic activity and proteolytic
activity of rPA is independent of each other.
3.8.3. Plasminogen Activation Assay. Similar to our previous
observations, the mutation of Asn12 and Asn278 signiﬁcantly
reduced the plasminogen activation property of rPA by
nearly 3- to 4-fold, (P = .0002) as depicted in Figure 6(c).
Theplasminogenbindingactivityofretavasewasfoundtobe6 Advances in Hematology
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Figure 4: SDS-PAGE analysis of Pichia derived native rPA and
its mutants. M: Medium protein molecular weight marker (97
to 14kDa); lane 1: native rPA (∼55kDa); lane 2: (N12P mutant
∼43kDa); lane 4: (N12P, N278S mutant, ∼39kDa); lane 4: (N278S,
∼43kDa) lane 5: GS115 control.
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Figure 5: ELISA for rPA quantitation in Pichia fermentation super-
natants. X axis shows sample types, Y axis is rPA concentration
(mg/L).
similartocrudePichiarPA(Figure 6(c)).Thisresultindicates
that the plasminogen binding property of the serine protease
domain of rPA is indeed aﬀected by asparagine mutation.
4. Discussion
Yeast is often preferred for expression of recombinant pro-
teins from higher eukaryotes. Like bacteria, yeast cultivation
is fast at low cost and a large variety of techniques exist for
the production and manipulation of the proteins produced.
Yeast, however, possess the speciﬁc advantage over bacterial
production systems in that they provide an environment
for posttranslational modiﬁcation andsecretion (e.g. acyla-
tion, phosphorylation, glycosylation, formation of disulﬁde
bonds). These modiﬁcations are often essential for the
function and/or stability of the expressed protein. Although
yeast-like Kluyveromyces lactis has been employed of rPA
expression,theyieldisratherlowassuggested[17].Sinceitis
claimed that the pharmacokinetic properties of a tPA variant
isbetterwithdeglycosylatedversion[16],itseemsimperative
that our present study assumes critical importance.
Methylotrophic yeast has gained increasing interest for
fundamental research and as attractive hosts for the produc-
tion of biologically active proteins [29, 30]. Although, the
nonglycosylated, truncated tPA (rPA, Retavase) produced in
E. coli in form of inclusion bodies is biologically active form
available commercially for therapeutic use, our present data
on loss of protease activity and enhanced clot lysis activity
obtained with Asp-278 mutation highlights the criticality of
this asparagine residue of rPA for the ﬁrst time with no eﬀect
on its expression levels. On the other side, the asparagine
mutation of the kringle 2 domain reduced both the protease
and the clot lysis activity signiﬁcantly and this observation is
being reported for the ﬁrst time.
The observations of complete loss of protease activity
seen with the rPA double mutant along with the slowest
clot lysis activity (t1/2 = 49min) as compared to the
single mutated rPA clones like N12P or N278S reiterates the
dominantroleplayedbytheasparagineresidueofthekringle
2 domain in regulating the ﬁbrinolytic activity of rPA.
Work by Collen et al. [31] have shown the increased
catalyticeﬃciencyforplasminogenactivationbysitedirected
mutagenesis of tPA in the kringle domains and recently a
paper by Lee et al. [32] showed antiendothelial property of
just the kringle 1 and 2 domains in Pichia pastoris with no
glycosylation are research work carried out on similar lines.
This ﬁbrin aﬃnity is believed to be due to interactions of
the ﬁnger and kringle 2 domain with ﬁbrin. For reasons
poorly understood, kringle 1 domain interacts more weakly
than kringle 2 with ﬁbrin [33]. The diﬀerent aﬃnities might
be due to diﬀerent orientations of the domains relative to
the serine protease domain. Certain amino acid residues
in the plasminogen-binding region of the tPA protease
domain provide favorable binding energies for portions of
the plasminogen molecule and that these interactions can be
increased by substitution of diﬀerent amino acids at these
positions [33].
Thereducedplasminogen activity foralltherPAmutants
also supports the claims of the residence of the plasminogen
binding domain in the protease domain of tPA [34]. Our
observations of diﬀerential eﬀect of asparagine mutations
on protease and clot lysis activity correlates with similar
observations of Wang et al. [35] for another plasminogen
activator molecule urokinase. It is possible to speculate that
theAsn278 substitutionwithserinehasmodiﬁedthetopology
of the rPA molecule for enhanced ﬁbrin binding and thereby
enhanced clot lysis. Our data supports the observations of
Paoni et al. [36] that substitutions of the protease domain
of tissue plasminogen activator at four sites including I275
enhanced ﬁbrin binding.
Our results on loss of serine protease activity of rPA
upon asparagines substitutions support the observations of
a recent report on role of asparagine-linked glycosylation site
on matriptase, a transmembrane serine protease [26]a n d
contribution of asparagines in maintaining the structural
integrity of a cysteine protease-like papain [25].
Our present data reﬂecting high yields of rPA to a
tune of 250mg/L in shake ﬂask is comparable to literature
reports, although in a nonoptimized medium. This could be
attributed to high copy number of the rPA gene integratedAdvances in Hematology 7
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Figure 6: (a) Protease activity assay for rPA and its mutants. Sample 1 is WT (wild type rPA gene); sample 2: N12P, N278S double mutant;
sample 3: N12P mutant; sample 4: N278S mutant; sample 5: commercial retavase preparation. (b) Clot lysis activity by turbidimetric
ﬁbrinolytic assay. X axis shows incubation time in minutes for clot lysis while Y axis shows % clot lysis. The horizontal line indicates 50%
clotlysiswhiletheverticaldottedlinesindicatethet 1/2 valuesofdiﬀerentrPAsamples.Thecourseofclotlysisisdemonstratedbyconnecting
data points of diﬀerent time intervals. (c) Plasminogen activation assay. X axis shows sample types while Y axis shows absorbance at 405nm.
Sample 1: WT rPA; sample 2: N12P, N278S double mutant; sample 3: N12P mutant; sample 4: N278S mutant; sample 5: commercial retavase
preparation.
into the Pichia genome. It is worth mentioning at this stage
that the rPA expression was seen on all the fermentation
days without any signs of degradation and this is in contrast
to the previous observations of Shu-guang et al. [11]w h o
reported degradation of Pichia derived rPA during routine
fermentation conditions.
It is worth mentioning here that the activity observed
for the crude Pichia derived native rPA is comparable
to bacterial-derived commercial rPA preparation and thus
hints towards the potential possibility of achieving better
rPA preparations from Pichia. Moreover, achieving better
clot lysis activity with the present rPA mutants opens up
the possibility of development of next generation reteplase
molecules for improved therapeutic use.
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